BLUE Jan 2025 5.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.0700

-0.0300

(-30.00%)

As of 10:35AM EDT. Market open.

Loading interactive chart…

GuruFocus.com
bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
Detailed Analysis of Financial Performance and Future Outlook
Zacks
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Business Wire
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.